ITOVEBI®

Drug Information Related Patent

Hold Company

GENENTECH INC

Learn More

Dosage and Administration

TABLET;ORAL

Specification

3MG; 9MG

Indication

Itovebi®, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

Use

Instructions for Use

API

INAVOLISIB

API Structure

We Supply

INAVOLISIB

Drug Patent

Patent No	Expiration Date
10851091	2036/7/1
11028100	2038/4/26
11760753	2036/7/1
8242104	2030/9/27
8343955	2030/9/27
9650393	2036/7/1

API Patent

Patent No	Expiration Date
10851091	2036/7/1
11760753	2036/7/1
8242104	2030/9/27
8343955	2030/9/27
9650393	2036/7/1

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION